U.S. Peripheral Liquid Embolic Agents Market Size, Share, Trends And Forecast (2026-2036) Featuring Profiles Of Boston Scientific Corp., Terumo Medical Corp. (Microvention), Blackswan Vascular (Sirtex Medical), And Instylla
Dublin, Nov. 12, 2026 (GLOBE NEWSWIRE) -- "U.S. Peripheral Liquid Embolic Agents Market Size, Share & Trends Analysis Report 2026-2036" has been added to ResearchAndMarkets.com's offering.
The U.S. peripheral liquid embolic agents market was valued at USD 99.7 million in 2025 and is projected to increase from USD 110.3 million in 2026 to USD 222.7 million by 2036. The market is expected to expand at a compound annual growth rate of 7.3% from 2026 to 2036, supported by rising demand for minimally invasive vascular interventions and continued advances in embolization technologies.
The increasing prevalence of peripheral artery disease (PAD) and other vascular disorders is contributing to the need for effective peripheral vascular procedures across the U.S. Minimally invasive endovascular treatments continue to gain adoption due to reduced surgical trauma, shorter hospital stays, and faster patient recovery. Wider access to interventional radiology services, combined with improvements in catheter-based techniques, is also supporting the use of liquid embolic agents in complex vascular procedures.
Growth in the U.S. peripheral liquid embolic agents market is further driven by the expanding role of embolization in interventional oncology. The rising cancer burden is increasing the number of patients requiring peripheral vascular embolization for hypervascular tumor management. Transarterial embolization (TAE) and transarterial chemoembolization (TACE) are increasingly used to selectively occlude tumor-feeding vessels, creating demand for technologies that enable controlled and targeted vessel occlusion.
Liquid embolic agents can penetrate distal and complex vascular networks while forming an occlusive cast within targeted vessels. Their use is expanding in image-guided embolization procedures for liver cancer and other hypervascular tumors. Advances in microcatheter delivery systems and embolic materials are expected to broaden clinical applications and improve procedural precision.
Embolization therapies represented a substantial share of the U.S. interventional oncology procedures market in 2025, with liver cancer accounting for the largest cancer-type segment. According to the American Cancer Society, approximately 42,240 new cases of primary liver and intrahepatic bile duct cancer were expected in the U.S. in 2025, along with about 30,090 deaths. These figures highlight the need for effective treatment approaches, including transarterial embolization procedures.
Market Segmentation
The report provides country-level revenue forecasts and analysis of industry trends across U.S. peripheral liquid embolic agents market sub-segments. The market is evaluated by product, application, and end-use for the period from 2021 to 2036.
Product Outlook (Revenue, USD Million, 2021 - 2036)
- Ethylene Vinyl Alcohol Copolymer (EVOH) Others
Application Outlook (Revenue, USD Million, 2021 - 2036)
- Peripheral Vascular Hemorrhage Hypervascular Tumors Peripheral Vascular Malformations / AVMs Aneurysms / Pseudoaneurysms Type II Endoleaks Portal Vein Embolization (PVE) Venous Applications (varicocele, PCS, varicose veins) Other Peripheral Embolization Applications
End-use Outlook (Revenue, USD Million, 2021 - 2036)
- Hospitals & Interventional Radiology (IR) Suites Ambulatory Surgical Centers (ASCs) Specialty Clinics / Vascular Centers Others
Key Benefits of the Report
- Detailed U.S. market analysis across major product, application, and end-use segments Revenue estimates and forecasts supporting market assessment and strategic planning Analysis of growth opportunities, emerging technologies, and industry trends Competitive landscape insights covering key market participants and market presence Evaluation of product innovation and developments affecting peripheral embolization Actionable intelligence to identify potential revenue opportunities and support informed business decisions
The report offers market intelligence for healthcare companies, medical device manufacturers, investors, interventional radiology providers, and other industry stakeholders. Its analysis of market growth, segment performance, competitive strategy, and evolving clinical applications supports decision-making within the expanding U.S. peripheral liquid embolic agents market.
Companies Featured
- Boston Scientific Corporation Terumo Medical Corporation (MicroVention) BlackSwan Vascular (Sirtex Medical) Instylla, Inc.
For more information about this report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment